24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
CytoReason
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:27
25-year-old AI investor’s $16 billion bet hits a brutal reality check
11:09
Israel’s cyber industry bets identity will become the next AI security battleground
10:13
Israeli startups raised $1.5 billion in July as investors doubled down on enterprise AI
09:48
Why Israel may need to take its most secret missile maker public
More stories
Buzz
Most popular
Daily
Weekly
1
Israel searches for technology that could find soldiers and pilots who cannot call for help
2
Another 10 U.S. tankers are headed to Israel's Ben Gurion as airport delays mount
3
After IAI and Rafael, secretive missile engine maker Tomer moves toward an IPO
4
ServiceNow continues layoffs as it restructures around AI
5
Israel's Iron Dome and Arrow makers unlikely to reach the IPO market before 2027 as Tomer joins the queue
More news
CytoReason
4 stories about CytoReason
CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models
17.07.24
|
Meir Orbach
The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform
20.09.22
|
Meir Orbach
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason
10.01.19
|
Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars